Cost-utility of adjuvant high-dose interferon alpha therapy in stage III cutaneous melanoma in Quebec.
Crott
R
R
Faculty of Pharmacy, University of Montreal, Canada. Ralph.crott@skyne.be
Ali
F
F
Burdette-Radoux
S
S
D000328:Adult; D000465:Algorithms; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000191:economics*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D003198:Computer Simulation; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006304:Health Status; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000191:economics*; D008390:Markov Chains; D008545:Melanoma / Q000188:drug therapy* / Q000191:economics* / Q000401:mortality; D008875:Middle Aged; D009010:Monte Carlo Method; D009364:Neoplasm Recurrence, Local / Q000191:economics; D011788:Quality of Life; D011792:Quebec; D012306:Risk; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000191:economics* / Q000401:mortality; D012984:Software; D016019:Survival Analysis; D013727:Terminal Care / Q000191:economics; D013997:Time Factors
D000970:Antineoplastic Agents; D016898:Interferon-alpha